ASP1517 Phase 3 Clinical Trial - A Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2017 Planned End Date changed from 1 Sep 2017 to 30 Jun 2018.
- 14 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Jun 2018.